epalrestat

Also Known As:

3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine; ONO 2; ONO 2235; ONO-2; ONO-2235; 3-thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)-

Networked: 130 relevant articles (25 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiazolidines: 105
      - epalrestat: 130
    - Rhodanine: 61
      - epalrestat: 130
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Rhodanine: 61
        epalrestat: 130

Experts

1.	Sato, Keisuke: 6 articles (04/2021 - 01/2013)
2.	Tatsunami, Ryosuke: 6 articles (04/2021 - 01/2013)
3.	Murao, Yu: 5 articles (04/2021 - 01/2013)
4.	Tampo, Yoshiko: 4 articles (04/2021 - 01/2013)
5.	Yama, Kaori: 4 articles (04/2021 - 01/2013)
6.	Hotta, N: 3 articles (12/2012 - 06/2001)
7.	Kawamori, Ryuzo: 3 articles (01/2009 - 07/2006)
8.	Hotta, Nigishi: 3 articles (09/2007 - 03/2003)
9.	Choudhary, Shalki: 2 articles (01/2022 - 01/2021)
10.	Hopper, Waheeta: 2 articles (01/2022 - 01/2019)

Related Diseases

1.	Diabetic Neuropathies (Diabetic Neuropathy) 10/01/2008 - "Although data are limited, it is strongly suggested that epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy." 05/01/1996 - "Although data are limited, they strongly suggest that epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy." 11/01/1993 - "Epalrestat 150 mg/day for 12 weeks improved motor and sensory nerve conduction velocity, and vibration threshold compared with baseline and placebo in patients with diabetic neuropathy. " 04/01/2021 - "The purpose of the present study was to determine whether epalrestat (EPS), which is used for the treatment of diabetic neuropathy, protects against Cd-induced cytotoxicity in bovine aortic endothelial cells (BAECs). " 01/01/2021 - "The purpose of the present study was to determine whether epalrestat (EPS), which is used for the treatment of diabetic neuropathy, suppresses inflammatory response in LPS-stimulated RAW264.7 cells. "
2.	Peripheral Nervous System Diseases (PNS Diseases) 02/01/2007 - "Is epalrestat an effective treatment for diabetic peripheral neuropathy?" 06/15/2017 - "Epalrestat is clinically applied for the management of diabetic peripheral neuropathy, yet its pharmacokinetic properties are not well understood. " 11/01/2010 - "Epalrestat suppressed the deterioration of diabetic peripheral neuropathy, especially in the lower extremity. " 10/01/2009 - "[Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course]." 03/01/2005 - "Eight type 2 diabetic patients with peripheral neuropathy were administered with the ARI epalrestat (150 mg/day) for 90 days, and esophageal pH and motility were monitored before and after the ARI treatment. "
3.	Diabetes Complications 07/01/2008 - "Stratified subgroup analyses revealed significantly better efficacy of epalrestat in patients with good glycaemic control and less severe diabetic complications. " 09/01/2007 - "A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT)." 01/01/2023 - "Importantly, it could be regarded as a safe intervention for RA patients who need epalrestat for the treatment of diabetic complications." 11/01/1993 - "The suggested ability of epalrestat to prevent the onset of diabetic complications should also be investigated. " 01/01/2017 - "Importantly, epalrestat, an AKR1B1 inhibitor that has been approved for the treatment of diabetic complications, significantly suppresses CSC properties, tumorigenicity, and metastasis of BLBC cells. "
4.	Diabetic Nephropathies (Diabetic Nephropathy) 06/01/2004 - "These results indicate that diabetic nephropathy involves distorted cell function of renal tubules, and that treatment with epalrestat may prevent at least the progress of the nephropathy." 11/01/1995 - "The present study was conducted in order to determine whether an aldose reductase inhibitor (ARI), epalrestat, prevents the progression of diabetic nephropathy in rats. " 01/01/2020 - "To investigate the changes of renal blood flow parameters in patients with early-stage diabetic nephropathy (DN) treated with Aldose reductase inhibitors (ARI)/Epalrestat. " 01/01/2019 - "The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation." 09/01/2001 - "Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients."
5.	Type 2 Diabetes Mellitus (MODY) 03/01/1999 - "Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus." 06/01/1997 - "These data suggest that epalrestat may be a useful drug to prevent infection by improving the impaired O2- and OCl- generation by neutrophils from poorly controlled NIDDM patients." 09/01/2001 - "The aim of the present study was to elucidate the long-term effect of epalrestat, an aldose reductase inhibitor (ARI), on renal function in patients with type 2 diabetes mellitus showing microalbuminuria. " 01/01/2009 - "Given the importance of measuring lipid hydroperoxides in erythrocytes as an index of oxidative stress, these results highlight the potential usefulness of epalrestat in reducing oxidative stress in type 2 diabetes mellitus." 03/01/1999 - "To evaluate the effect of long-term administration of an aldose reductase inhibitor on diabetic cardiovascular autonomic neuropathy, 22 subjects with non-insulin dependent diabetes mellitus (NIDDM, 11 men and 11 women, mean age; 64.8 +/- 7.8 years, duration of diabetes; 18.3 +/- 5.6 years) were administered epalrestat, one type of aldose reductase inhibitor, for 36 months. "

Related Drugs and Biologics

1.	Aldehyde Reductase (Aldose Reductase)
2.	Sorbitol (Yal)
3.	Glucose (Dextrose)
4.	Thioctic Acid (Lipoic Acid)
5.	polyol
6.	NAD (NADH)
7.	Alprostadil (Muse)
8.	Congenital disorder of glycosylation type 1A
9.	Nerve Growth Factor (NGF)
10.	Lactic Acid (Lactate)

Related Therapies and Procedures

1.	Therapeutics
2.	Lasers (Laser)
3.	Oral Administration
4.	Premedication
5.	Ligation